Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 7Other hematologic neoplasm 7Lymphoid 5CNS 5Gastrointestinal 4Dermatologic 4Thoracic 3Sarcoma 3Genitourinary 3Tumor-Agnostic 1Myeloid 1Gynecologic 1Breast 1

Conditions

Prostatic Neoplasms 1Castration Levels of Testosterone 1Carcinoma, Transitional Cell 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × selinexor × Genitourinary × Clear all
NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

University of California, Davis

Phase 1/2 Terminated
4 enrolled 8 charts
Genitourinary

Carcinoma, Transitional Cell

NCT02146833 2023-01-26

SHIP

Karyopharm Therapeutics Inc

Phase 2 Terminated
20 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT02215161 2018-06-26

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
14 enrolled 12 charts
Genitourinary

Castration Levels of Testosterone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡